FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

rraogco,	2.0.200.0	

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								
	OMB Number: Estimated average burde								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WILSON TROY EDWARD				2. Issuer Name and Ticker or Trading Symbol Kura Oncology, Inc. [KURA]					(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
						000		-			X Director		10% Ov		
(Last)	(F	irst)	(Middle)	3	Date of Earliest Transaction (Month/Day/Year)					-	X Officer below)	(give title	Other (s below)	pecify	
KURA ONCOLOGY, INC.				01/23/2017						President and CEO					
11119 N. TORREY PINES ROAD, SUITE 125															
,				4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)		Δ.	02027									,	ed by One R	eporting Persor	,
LA JOLI	LA C.	A	92037										•	han One Repor	
(City)	(S	tate)	(Zip)									Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				Transaction ate atelonth/Day/	Execution Da		ion Date, Transaction Code (Instr.		on Dispose	Securities Acquired (A) of isposed Of (D) (Instr. 3, 4		5. Amour Securities Beneficia Owned For	s Form Illy (D) o ollowing (I) (In	orm: Direct D) or Indirect) (Instr. 4)	7. Nature of ndirect Beneficial Ownership
							Code V	Amount	(A) o	r Price	Transacti (Instr. 3 a	on(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	conversion r Exercise (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) 8)		Transa Code	nsaction Derivative		Expiration Date of S (Month/Day/Year) Un De		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Option to purchase common stock	\$6.15	01/23/2017		A		236,000		(1)	01/22/2027	Common Stock	236,000	\$0.00	236,000	D	

Explanation of Responses:

1. This option vests in 48 equal monthly installments commencing on the grant date.

Remarks:

<u>Heidi Henson, Attorney-in-fact</u> <u>for Troy Wilson</u>

01/25/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.